Antonio Montoto-Marqués
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Antonio Montoto-Marqués has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Sebastián Salvador-De la Barrera
Unidad de Lesionados medulares, Complejo Hospitalario Universitario de A Coruña
20 shared publications - Antonio Rodríguez-Sotillo
Unidad de Lesionados Medulares, Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), La Coruña, España
12 shared publications - Rita Galeiras
Unidad de Cuidados Intensivos, Complexo Hospitalario Universitario de A Coruña, A Coruña, España
8 shared publications M E Ferreiro-Velasco
Unidad de Lesionados Medulares, Complexo Hospitalario Universitario A Coruña (CHUAC), Coruña, Spain
4 shared publications- María Elena Ferreiro-Velasco
Unidad de Lesionados medulares, Complejo Hospitalario Universitario de A Coruña
4 shared publications - Joan Vidal
Guttmann Neurorehabilitation Institute, Universitat Autònoma de Barcelona, Badalona, Spain
3 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by SAGE Publications in Clinical Rehabilitation
Development and external validation of quality indicators for Neurorehabilitation Units: The REHABest Delphi study
Objective: To develop a consensus-based framework of quality indicators for Neurorehabilitation Units. Design: Delphi consensus study with two-phase external validation. Setting: Expert consultation and external validation were conducted through online questionnaires. Participants: Twelve neurorehabilitation experts participated in the Delphi process. External validation involved 63 independent specialists and a multidisciplinary panel of nine professionals. Intervention: Development of quality indicators through a three-round Delphi process following Conducting and REporting DElphi Studies (CREDES) recommendations. Main measures: Expert agreement on candidate indicators, with consensus defined a priori as ≥75%. Results: An initial qualitative expert-generation phase produced 38 candidate indicators. These were subsequently refined through three Delphi rounds, during which indicators were retained, merged, reformulated, added, or disaggregated according to expert consensus and accreditation level. The final framework comprised 50 indicators categorized into structure (21), process (13), and outcome (16) domains. External validation confirmed the relevance and clarity of the framework, although implementation challenges were identified in centres with heterogeneous resources. Conclusions: The proposed framework provides a structured set of quality indicators that may support quality assessment, accreditation, and continuous improvement in neurorehabilitation services.
- 18 August 2026
- Published by SAGE Publications in Clinical Rehabilitation
Open AccessDevelopment and external validation of quality indicators for Neurorehabilitation Units: The REHABest Delphi study
Objective: To develop a consensus-based framework of quality indicators for Neurorehabilitation Units. Design: Delphi consensus study with two-phase external validation. Setting: Expert consultation and external validation were conducted through online questionnaires. Participants: Twelve neurorehabilitation experts participated in the Delphi process. External validation involved 63 independent specialists and a multidisciplinary panel of nine professionals. Intervention: Development of quality indicators through a three-round Delphi process following Conducting and REporting DElphi Studies (CREDES) recommendations. Main measures: Expert agreement on candidate indicators, with consensus defined a priori as ≥75%. Results: An initial qualitative expert-generation phase produced 38 candidate indicators. These were subsequently refined through three Delphi rounds, during which indicators were retained, merged, reformulated, added, or disaggregated according to expert consensus and accreditation level. The final framework comprised 50 indicators categorized into structure (21), process (13), and outcome (16) domains. External validation confirmed the relevance and clarity of the framework, although implementation challenges were identified in centres with heterogeneous resources. Conclusions: The proposed framework provides a structured set of quality indicators that may support quality assessment, accreditation, and continuous improvement in neurorehabilitation services.
- Open Access
- 26 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 762
Mesenchymal Stromal/Stem Cells in Chronic Incomplete Traumatic Spinal Cord Injury: A Phase I/II Double-Blind Placebo-Controlled Multicentre Trial
Background/Objectives: Chronic traumatic spinal cord injury (SCI) causes persistent neurological deficits for which no clinically effective regenerative therapy is currently available. Mesenchymal stromal/stem cells (MSCs), particularly Wharton’s jelly-derived MSCs (WJ-MSCs), demonstrate immunomodulatory and neurotrophic potential. This phase I/II study evaluated the safety and efficacy of intrathecal allogeneic WJ-MSC administration in individuals with chronic incomplete cervical SCI. Methods: In this multicentre, randomised, double-blind, placebo-controlled trial (NCT05054803, EudraCT 2021-000346-18), 18 participants with chronic (1–5 years post-injury) incomplete cervical SCI (AIS B–D) received two intrathecal injections of WJ-MSCs (0.7–1.3 × 106 viable cells/kg) or a placebo at baseline and 3 months. Seventeen participants completed the 12-month follow-up. Primary outcomes assessed safety, and secondary endpoints included International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor and sensory scores, spasticity, neuropathic pain, functional independence, neurophysiological measures, and quality of life. Results: Intrathecal WJ-MSC administration was safe and well tolerated. Eighty adverse events occurred (placebo: 26; WJ-MSC: 54), predominantly mild or moderate; four severe events were unrelated to treatment. Both groups demonstrated significant within-group improvements in total motor scores at 12 months, with no between-group difference. No treatment effects were observed for sensory scores, electrophysiological measures, functional independence, spasticity, pain, or patient-reported outcomes. Conclusions: In this first randomised, placebo-controlled trial evaluating intrathecal WJ-MSCs in chronic incomplete cervical SCI, WJ-MSC administration demonstrated a favourable safety profile; however, no significant between-group differences were detected relative to the placebo. Given the limited sample size and early-phase design, the efficacy findings should be interpreted cautiously. Future research should explore enhanced cell products, intensified dosing schedules, optimised delivery strategies, early intervention, and multimodal therapeutic combinations.
- 26 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 762
Open AccessMesenchymal Stromal/Stem Cells in Chronic Incomplete Traumatic Spinal Cord Injury: A Phase I/II Double-Blind Placebo-Controlled Multicentre Trial
Background/Objectives: Chronic traumatic spinal cord injury (SCI) causes persistent neurological deficits for which no clinically effective regenerative therapy is currently available. Mesenchymal stromal/stem cells (MSCs), particularly Wharton’s jelly-derived MSCs (WJ-MSCs), demonstrate immunomodulatory and neurotrophic potential. This phase I/II study evaluated the safety and efficacy of intrathecal allogeneic WJ-MSC administration in individuals with chronic incomplete cervical SCI. Methods: In this multicentre, randomised, double-blind, placebo-controlled trial (NCT05054803, EudraCT 2021-000346-18), 18 participants with chronic (1–5 years post-injury) incomplete cervical SCI (AIS B–D) received two intrathecal injections of WJ-MSCs (0.7–1.3 × 106 viable cells/kg) or a placebo at baseline and 3 months. Seventeen participants completed the 12-month follow-up. Primary outcomes assessed safety, and secondary endpoints included International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor and sensory scores, spasticity, neuropathic pain, functional independence, neurophysiological measures, and quality of life. Results: Intrathecal WJ-MSC administration was safe and well tolerated. Eighty adverse events occurred (placebo: 26; WJ-MSC: 54), predominantly mild or moderate; four severe events were unrelated to treatment. Both groups demonstrated significant within-group improvements in total motor scores at 12 months, with no between-group difference. No treatment effects were observed for sensory scores, electrophysiological measures, functional independence, spasticity, pain, or patient-reported outcomes. Conclusions: In this first randomised, placebo-controlled trial evaluating intrathecal WJ-MSCs in chronic incomplete cervical SCI, WJ-MSC administration demonstrated a favourable safety profile; however, no significant between-group differences were detected relative to the placebo. Given the limited sample size and early-phase design, the efficacy findings should be interpreted cautiously. Future research should explore enhanced cell products, intensified dosing schedules, optimised delivery strategies, early intervention, and multimodal therapeutic combinations.
- 9 February 2026
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 49 (5) , 1083-1094
Mortality after traumatic spinal cord injury in Galicia, Spain
To analyze mortality, causes of death and survival in patients with traumatic spinal cord injury (TSCI) in Galicia after discharge; compare global mortality and cause-specific mortality against the Galician population; and describe risk factors for mortality. A retrospective cohort study. A spinal cord injury Unit from a tertiary referral hospital. A cohort of TSCI patients discharged between January 2011 and December 2021. Causes of death (ICD-10) and survival time were obtained from the electronic health record. Global mortality and cause-specific mortality were compared with the Galician population using standardized mortality ratios (SMR). Survival was analyzed using the Kaplan-Meier method. Risk factors were studied using a Cox proportional hazards regression model. A total of 438 patients were included (74.89% men), of whom 122 died by 30 June 2024. Mean survival time was 122 months. Survival was decreased in older patients, those with complete cervical injuries and women. TSCI patients had an increased mortality (SMR 2.2) compared with the Galician population. The most common causes of death were respiratory diseases. Cause-specific SMRs were significantly increased for respiratory diseases (SMR 10.22), urinary tract diseases (SMR 16.92) and pressure ulcers (SMR 37.74). Risk factors for mortality were mechanical ventilation or tracheostomy at discharge, having an indwelling catheter at discharge, and destination place at discharge different from the patient´s previous home. TSCI patients in Galicia, especially women and older patients, have an increased mortality. Respiratory diseases are the most common cause of death. Special attention should be paid to respiratory management and destination after discharge.
- 9 February 2026
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 49 (5) , 1083-1094
Mortality after traumatic spinal cord injury in Galicia, Spain
To analyze mortality, causes of death and survival in patients with traumatic spinal cord injury (TSCI) in Galicia after discharge; compare global mortality and cause-specific mortality against the Galician population; and describe risk factors for mortality. A retrospective cohort study. A spinal cord injury Unit from a tertiary referral hospital. A cohort of TSCI patients discharged between January 2011 and December 2021. Causes of death (ICD-10) and survival time were obtained from the electronic health record. Global mortality and cause-specific mortality were compared with the Galician population using standardized mortality ratios (SMR). Survival was analyzed using the Kaplan-Meier method. Risk factors were studied using a Cox proportional hazards regression model. A total of 438 patients were included (74.89% men), of whom 122 died by 30 June 2024. Mean survival time was 122 months. Survival was decreased in older patients, those with complete cervical injuries and women. TSCI patients had an increased mortality (SMR 2.2) compared with the Galician population. The most common causes of death were respiratory diseases. Cause-specific SMRs were significantly increased for respiratory diseases (SMR 10.22), urinary tract diseases (SMR 16.92) and pressure ulcers (SMR 37.74). Risk factors for mortality were mechanical ventilation or tracheostomy at discharge, having an indwelling catheter at discharge, and destination place at discharge different from the patient´s previous home. TSCI patients in Galicia, especially women and older patients, have an increased mortality. Respiratory diseases are the most common cause of death. Special attention should be paid to respiratory management and destination after discharge.
- Open Access
- 24 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2203
Advances and New Therapies in Traumatic Spinal Cord Injury
Recovery from traumatic spinal cord injury (tSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. At the clinical level, the fundamental pillars of treatment are the reduction in secondary damage (neuroprotection) and rehabilitation; these are the tools we have to mitigate the disability caused by spinal cord injury (SCI). To date, the treatments on which neuroprotection has been based are the prevention of acute respiratory failure to avoid hypoxia, early hemodynamic control, neuroprotective drugs and surgical management. Optimizing early hemodynamic control to ensure adequate spinal cord perfusion may be key to the management of SCI. While neuroprotective agents like methylprednisolone have fallen into disuse, several promising therapies are currently being tested in clinical trials. In terms of surgical treatment, although their impact on neurological recovery remains debated, appropriate early bone decompression followed by duroplasty in selected cases is increasingly recommended. Advances in cell therapies hold significant potential for enhancing both clinical and functional outcomes in SCI patients. Moreover, emerging neuromodulation techniques, such as transcutaneous and epidural stimulation, along with innovations in rehabilitation technologies—such as robotic systems and exoskeletons—are becoming indispensable tools for improving locomotion and overall mobility in individuals with SCI. This article provides an update on the advances in neuroprotection against secondary damage caused by tSCI, in cellular therapies, and in new rehabilitation therapies.
- 24 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2203
Open AccessAdvances and New Therapies in Traumatic Spinal Cord Injury
Recovery from traumatic spinal cord injury (tSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. At the clinical level, the fundamental pillars of treatment are the reduction in secondary damage (neuroprotection) and rehabilitation; these are the tools we have to mitigate the disability caused by spinal cord injury (SCI). To date, the treatments on which neuroprotection has been based are the prevention of acute respiratory failure to avoid hypoxia, early hemodynamic control, neuroprotective drugs and surgical management. Optimizing early hemodynamic control to ensure adequate spinal cord perfusion may be key to the management of SCI. While neuroprotective agents like methylprednisolone have fallen into disuse, several promising therapies are currently being tested in clinical trials. In terms of surgical treatment, although their impact on neurological recovery remains debated, appropriate early bone decompression followed by duroplasty in selected cases is increasingly recommended. Advances in cell therapies hold significant potential for enhancing both clinical and functional outcomes in SCI patients. Moreover, emerging neuromodulation techniques, such as transcutaneous and epidural stimulation, along with innovations in rehabilitation technologies—such as robotic systems and exoskeletons—are becoming indispensable tools for improving locomotion and overall mobility in individuals with SCI. This article provides an update on the advances in neuroprotection against secondary damage caused by tSCI, in cellular therapies, and in new rehabilitation therapies.
- Open Access
- 19 June 2024
- Published by Springer Nature in Spinal Cord
- Vol. 62 (8) , 454-467
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Study design: Double-blind, randomized, placebo-controlled, parallel-group multicentric phase IIA clinical trial. Objective: To assess the safety and tolerability of oral administration of NFX-88 in subjects with chronic spinal cord injury (SCI) and explore its efficacy in pain control. Setting: A total of 7 spinal cord injury rehabilitation units in Spain. Methods: A total of 61 adult with traumatic complete or incomplete spinal cord injury (C4-T12 level), were randomised 1:1:1:1 to a placebo, NFX88 1.05 g, 2.1 g, 4.2 g/day for up to 12 weeks. The placebo or NFX-88 was administered as add-on therapy to pre-existing pregabalin (150–300 mg per day). Safety and tolerability were evaluated, and the Visual Analogue Scale (VAS) was the primary measure to explore the efficacy of NFX-88 in pain control. Results: No severe treatment-related adverse effects were reported for any of the four study groups. 44 SCI individuals completed the study and were analysed. The data obtained from the VAS analysis and the PainDETECT Questionnaire (PD-Q) suggested that the combination of NFX88 with pregabalin is more effective than pregabalin with placebo at reducing neuropathic pain (NP) in individuals with SCI and that the dose 2.10 g/day causes the most dramatic pain relief. Conclusions: NFX88 treatment was found to be highly safe and well tolerated, with the dose of 2.10 g/day being the most effective at causing pain relief. Thus, the promising efficacy of this first-in-class lipid mediator deserves further consideration in future clinical trials.
- 19 June 2024
- Published by Springer Nature in Spinal Cord
- Vol. 62 (8) , 454-467
Open AccessRandomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Study design: Double-blind, randomized, placebo-controlled, parallel-group multicentric phase IIA clinical trial. Objective: To assess the safety and tolerability of oral administration of NFX-88 in subjects with chronic spinal cord injury (SCI) and explore its efficacy in pain control. Setting: A total of 7 spinal cord injury rehabilitation units in Spain. Methods: A total of 61 adult with traumatic complete or incomplete spinal cord injury (C4-T12 level), were randomised 1:1:1:1 to a placebo, NFX88 1.05 g, 2.1 g, 4.2 g/day for up to 12 weeks. The placebo or NFX-88 was administered as add-on therapy to pre-existing pregabalin (150–300 mg per day). Safety and tolerability were evaluated, and the Visual Analogue Scale (VAS) was the primary measure to explore the efficacy of NFX-88 in pain control. Results: No severe treatment-related adverse effects were reported for any of the four study groups. 44 SCI individuals completed the study and were analysed. The data obtained from the VAS analysis and the PainDETECT Questionnaire (PD-Q) suggested that the combination of NFX88 with pregabalin is more effective than pregabalin with placebo at reducing neuropathic pain (NP) in individuals with SCI and that the dose 2.10 g/day causes the most dramatic pain relief. Conclusions: NFX88 treatment was found to be highly safe and well tolerated, with the dose of 2.10 g/day being the most effective at causing pain relief. Thus, the promising efficacy of this first-in-class lipid mediator deserves further consideration in future clinical trials.
- Open Access
- 20 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11719
Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review
Recovery from a traumatic spinal cord injury (TSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. Cell therapy, particularly with mesenchymal stem cells (MSCs), holds significant promise for TSCI treatment. This systematic review aims to analyze the efficacy, safety, and therapeutic potential of MSC-based cell therapies in TSCI. A comprehensive search of PUBMED and COCHRANE databases until February 2023 was conducted, combining terms such as “spinal cord injury,” “stem cells,” “stem cell therapy,” “mesenchymal stem cells,” and “traumatic spinal cord injury”. Among the 53 studies initially identified, 22 (21 clinical trials and 1 case series) were included. Findings from these studies consistently demonstrate improvements in AIS (ASIA Impairment Scale) grades, sensory scores, and, to a lesser extent, motor scores. Meta-analyses further support these positive outcomes. MSC-based therapies have shown short- and medium-term safety, as indicated by the absence of significant adverse events within the studied timeframe. However, caution is required when drawing generalized recommendations due to the limited scientific evidence available. Further research is needed to elucidate the long-term safety and clinical implications of these advancements. Although significant progress has been made, particularly with MSC-based therapies, additional studies exploring other potential future therapies such as gene therapies, neurostimulation techniques, and tissue engineering approaches are essential for a comprehensive understanding of the evolving TSCI treatment landscape.
- 20 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (14) , 11719
Open AccessMesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review
Recovery from a traumatic spinal cord injury (TSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. Cell therapy, particularly with mesenchymal stem cells (MSCs), holds significant promise for TSCI treatment. This systematic review aims to analyze the efficacy, safety, and therapeutic potential of MSC-based cell therapies in TSCI. A comprehensive search of PUBMED and COCHRANE databases until February 2023 was conducted, combining terms such as “spinal cord injury,” “stem cells,” “stem cell therapy,” “mesenchymal stem cells,” and “traumatic spinal cord injury”. Among the 53 studies initially identified, 22 (21 clinical trials and 1 case series) were included. Findings from these studies consistently demonstrate improvements in AIS (ASIA Impairment Scale) grades, sensory scores, and, to a lesser extent, motor scores. Meta-analyses further support these positive outcomes. MSC-based therapies have shown short- and medium-term safety, as indicated by the absence of significant adverse events within the studied timeframe. However, caution is required when drawing generalized recommendations due to the limited scientific evidence available. Further research is needed to elucidate the long-term safety and clinical implications of these advancements. Although significant progress has been made, particularly with MSC-based therapies, additional studies exploring other potential future therapies such as gene therapies, neurostimulation techniques, and tissue engineering approaches are essential for a comprehensive understanding of the evolving TSCI treatment landscape.
- 1 February 2022
- Published by Springer Nature in Spinal Cord
- Vol. 60 (6) , 533-539
Neurological recovery after traumatic spinal cord injury: prognostic value of magnetic resonance
Study design Retrospective observational study. Objectives Assess the relationship between Magnetic Resonance (MR) image patterns and neurological recovery in patients with Traumatic Spinal Cord Injury (TSCI). Setting Spinal cord injury unit in Spain. Methods Patients admitted for acute TSCI between January 2010 and December 2018 with a MR exam performed in the acute phase were selected. Five patterns were established: normal, single-level edema, multilevel edema, hemorrhage, and spinal cord transection. Comparisons between the ASIA Injury Severity (AIS) score and Motor Index (MI) at admission and at discharge were made. Results Collected 296 patients. Normal and cord transection patterns were excluded due to the low number of cases. Single-level edema pattern was primarily observed in cases with incomplete injuries, hemorrhage pattern in complete injuries, and multilevel edema pattern at similar percentages in complete and incomplete lesions. Improvement of the AIS score was found in 40.9% of single-level edema, 20.2% of multilevel edema, and 19.0% of hemorrhage (p = 0.042) patterns. By excluding the AIS grade D from the analyses, the figures increased to 70.3%, 52.2%, and 19.4% respectively (p < 0.001). This significant relationship was confirmed by multivariate analysis, although it was not as relevant as the examination according to ASIA-ISCoS performed at admission (p = 0.005 vs p < 0.001). Mean variation of the MI was also significantly different (p < 0.001) between the three groups: 22.6 ± 21.4 for single-level edema, 16.9 ± 21.1 for multilevel edema, and 4.5 ± 8.4 for hemorrhage. Conclusion MR injury patterns observed at the acute phase are associated with the possibility of improvement of the AIS score and MI.
- 1 February 2022
- Published by Springer Nature in Spinal Cord
- Vol. 60 (6) , 533-539
Neurological recovery after traumatic spinal cord injury: prognostic value of magnetic resonance
Study design Retrospective observational study. Objectives Assess the relationship between Magnetic Resonance (MR) image patterns and neurological recovery in patients with Traumatic Spinal Cord Injury (TSCI). Setting Spinal cord injury unit in Spain. Methods Patients admitted for acute TSCI between January 2010 and December 2018 with a MR exam performed in the acute phase were selected. Five patterns were established: normal, single-level edema, multilevel edema, hemorrhage, and spinal cord transection. Comparisons between the ASIA Injury Severity (AIS) score and Motor Index (MI) at admission and at discharge were made. Results Collected 296 patients. Normal and cord transection patterns were excluded due to the low number of cases. Single-level edema pattern was primarily observed in cases with incomplete injuries, hemorrhage pattern in complete injuries, and multilevel edema pattern at similar percentages in complete and incomplete lesions. Improvement of the AIS score was found in 40.9% of single-level edema, 20.2% of multilevel edema, and 19.0% of hemorrhage (p = 0.042) patterns. By excluding the AIS grade D from the analyses, the figures increased to 70.3%, 52.2%, and 19.4% respectively (p < 0.001). This significant relationship was confirmed by multivariate analysis, although it was not as relevant as the examination according to ASIA-ISCoS performed at admission (p = 0.005 vs p < 0.001). Mean variation of the MI was also significantly different (p < 0.001) between the three groups: 22.6 ± 21.4 for single-level edema, 16.9 ± 21.1 for multilevel edema, and 4.5 ± 8.4 for hemorrhage. Conclusion MR injury patterns observed at the acute phase are associated with the possibility of improvement of the AIS score and MI.
- 30 August 2021
- Published by Springer Nature in Spinal Cord
- Vol. 60 (3) , 274-280
Organ dysfunction as determined by the SOFA score is associated with prognosis in patients with acute traumatic spinal cord injury above T6
Study design This is a retrospective, observational study. Objectives To evaluate organ dysfunction in patients with an acute traumatic spinal cord injury (ATSCI) above T6 using the Sequential Organ Failure Assessment (SOFA) score to determine its association with mortality. Setting The study was performed at the intensive care unit (ICU) of a tertiary hospital in the northwest of Spain. Methods The study included 241 patients with an ATSCI above T6 who had been admitted to the ICU between 1998 and 2017. A descriptive analysis of all variables collected was performed to compare the survivors with the non-survivors. In addition, a logistic regression model was used in the multivariate analysis to identify variables that were independently associated with mortality. Results The results revealed significant differences between the survivors and non-survivors in terms of their age, Charlson Comorbidity Index, Glasgow Coma Scale score on admission, APACHE II score, SOFA score on day 0 and day 4, and delta SOFA 4–0 (ΔSOFA 4–0). The results of this multivariate analysis identified the following variables as independent predictors of intra-ICU mortality: age (OR = 1.05; 95% CI: 1. 01–1.08), SOFA score on day 0 (OR = 1.42; 95% CI: 1.13–1.78), ΔSOFA 4–0 (OR = 1.53; 95% CI: 1.25–1.87), and fluid balance on day 4 (OR = 1.16; 95% CI: 1.00–1.35). Conclusions The SOFA score is useful for evaluating organ dysfunction in patients with an ATSCI above T6. After adjusting the analysis for conventional variables, organ dysfunction on admission, changes in organ function between day 4 and day 0 (ΔSOFA 4–0), and fluid balance on day 4 were seen to be independently associated with mortality in our study.
- 30 August 2021
- Published by Springer Nature in Spinal Cord
- Vol. 60 (3) , 274-280
Organ dysfunction as determined by the SOFA score is associated with prognosis in patients with acute traumatic spinal cord injury above T6
Study design This is a retrospective, observational study. Objectives To evaluate organ dysfunction in patients with an acute traumatic spinal cord injury (ATSCI) above T6 using the Sequential Organ Failure Assessment (SOFA) score to determine its association with mortality. Setting The study was performed at the intensive care unit (ICU) of a tertiary hospital in the northwest of Spain. Methods The study included 241 patients with an ATSCI above T6 who had been admitted to the ICU between 1998 and 2017. A descriptive analysis of all variables collected was performed to compare the survivors with the non-survivors. In addition, a logistic regression model was used in the multivariate analysis to identify variables that were independently associated with mortality. Results The results revealed significant differences between the survivors and non-survivors in terms of their age, Charlson Comorbidity Index, Glasgow Coma Scale score on admission, APACHE II score, SOFA score on day 0 and day 4, and delta SOFA 4–0 (ΔSOFA 4–0). The results of this multivariate analysis identified the following variables as independent predictors of intra-ICU mortality: age (OR = 1.05; 95% CI: 1. 01–1.08), SOFA score on day 0 (OR = 1.42; 95% CI: 1.13–1.78), ΔSOFA 4–0 (OR = 1.53; 95% CI: 1.25–1.87), and fluid balance on day 4 (OR = 1.16; 95% CI: 1.00–1.35). Conclusions The SOFA score is useful for evaluating organ dysfunction in patients with an ATSCI above T6. After adjusting the analysis for conventional variables, organ dysfunction on admission, changes in organ function between day 4 and day 0 (ΔSOFA 4–0), and fluid balance on day 4 were seen to be independently associated with mortality in our study.
- 1 June 2019
- Vol. 72 (5) , 483-499
Spanish consensus document for the diagnosis, treatment and management of neurogenic bladder
OBJECTIVES: The purpose of this document is to establish practical recommendations on neurogenic bladder (NB) management based on scientific evidence and medical and nursing perspective in Spinal Cord Injury (SCI) Units as a first multidisciplinary consensual approach in Spain. METHODS: This paper reports results from the first modified Delphi consensus building exercise on this procedure. A committee of recognised opinion-leaders in rehabilitation and urology with special interest in NB was constituted. A working group formed by rehabilitation doctors, urologists and nursing staff of SCI and Neurorehabilitation Units of a number of Spanish hospitals and specialised centres associated with the panel of NB experts have prepared this document. RESULTS: This review provided an overview of the main aspects described by the different clinical guidelines already available and highlighted the need to focus on recommendations in special priority situations in which there was no consensus. In view of the considerable impact this condition has on quality of life, patients should be offered help to better understand the disorder and they should be taught how to use the treatment techniques to obtain satisfactory results and promote their autonomy. CONCLUSIONS: This article presents a version of guidelines for patients with NB. The guidelines define the clinical profile of patients to provide the best evidence-based care and also an overview of the current drug and surgical treatments of NB.
- 1 June 2019
- Vol. 72 (5) , 483-499
Spanish consensus document for the diagnosis, treatment and management of neurogenic bladder
OBJECTIVES: The purpose of this document is to establish practical recommendations on neurogenic bladder (NB) management based on scientific evidence and medical and nursing perspective in Spinal Cord Injury (SCI) Units as a first multidisciplinary consensual approach in Spain. METHODS: This paper reports results from the first modified Delphi consensus building exercise on this procedure. A committee of recognised opinion-leaders in rehabilitation and urology with special interest in NB was constituted. A working group formed by rehabilitation doctors, urologists and nursing staff of SCI and Neurorehabilitation Units of a number of Spanish hospitals and specialised centres associated with the panel of NB experts have prepared this document. RESULTS: This review provided an overview of the main aspects described by the different clinical guidelines already available and highlighted the need to focus on recommendations in special priority situations in which there was no consensus. In view of the considerable impact this condition has on quality of life, patients should be offered help to better understand the disorder and they should be taught how to use the treatment techniques to obtain satisfactory results and promote their autonomy. CONCLUSIONS: This article presents a version of guidelines for patients with NB. The guidelines define the clinical profile of patients to provide the best evidence-based care and also an overview of the current drug and surgical treatments of NB.